
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): **September 17, 2015**

BioCorRx Inc.

(Exact name of registrant as specified in its charter)

333-153381

(Commission File Number)

Nevada

(State or other jurisdiction of Incorporation)

26-0685980

(I.R.S. Employer Identification No.)

601 N. Parkcenter Drive, Suite 103

Santa Ana, California 92705

(Address of principal executive offices)

(714) 462-4880

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 2.02 Results of Operations and Financial Condition

The disclosure set forth in Item 7.01 of this Current Report on Form 8-K is hereby incorporated by reference into this Item 2.02.

Item 7.01 Regulation FD Disclosure

On September 17, 2015, BioCorRx, Inc. gave a presentation to investors at the Singular Research Conference in Los Angeles, California. The presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The presentation provides an overview of the Company's strategy, performance and future objectives.

The information in this Current Report and in the exhibit attached hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

The following exhibit is furnished herewith and this list is intended to constitute the exhibit index:

99.1 BioCorRx, Inc. Investor Presentation – September 2015.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BIOCORRX INC.

Date: September 21, 2015

By: /s/ Lourdes Felix

Lourdes Felix
Chief Financial Officer and Director

BioCorRx, Inc. (Ticker: BICX)

INVESTOR PRESENTATION

September 17, 2015



Safe Harbor Statement

The information in this investor presentation may include forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.

BioCorRx, Inc. Investor Snapshot

Ticker:	BICX	<i>BioCorRx, Inc. seeks to brand and expand addiction treatment by licensing its comprehensive and affordable medical recovery program to healthcare providers.</i>
Price:	\$0.049	
Market Cap.	\$7.68 million	
Revenue (ttm):	\$1.54 million	<ul style="list-style-type: none">➤ Unique, proven business model with largely fragmented competition➤ Opportunity to be a disruptor in a \$35 billion dollar market➤ Grew program sales over 400% in 2014➤ Took company from one location to 11 in just over a year➤ Became cash flow positive➤ Eliminated convertible debt➤ Positioned for accelerated growth and expansion
Qtrly. Revenue Growth:	92%	
Insider Ownership:	34%	
Long-term Debt:	\$1.3 million	

3



The Addiction Treatment Sector

- **Insurance Mandates Expand Addiction Treatment Coverage**
 - Substance abuse now included in 10 core health care mandated benefits
 - Increased treatment availability to Medicaid and individual/small group markets
- **Large, Fragmented Market**
 - No dominant player and no national branding in this industry currently
 - Growth market (\$35 billion a year addiction rehab market*)
 - Early signs of consolidation

* Source: Marketdata Enterprises

The Addiction Problem

<small>* per National Institute on Drug Abuse</small>	Health Care (annually)	Overall (annually)
Alcohol	\$30 Billion	\$235 Billion
Illicit Drugs	\$11 Billion	\$193 Billion

- 23.5 million Americans are addicted to drugs and alcohol*
 - 17 million adults in the U.S. are alcohol-dependent
 - 85% of people with alcohol abuse or dependence go untreated
 - Over 2 million people in the U.S. abuse prescription pain relievers
 - Heroin is most widely known illegal opiate; number of users estimated as high as 900,000
 - Total includes other substances besides alcohol and opioids.

*According to the Substance Abuse and Mental Health Services Administration's (SAMHSA's) National Survey on Drug Use and Health.

5

The Treatment Problem

Issue	Impact	Solution
Addiction not treated as chronic disease	High relapse rate	Research shows combining treatment medications with behavior therapy is the best way to ensure success for most patients
90% of programs rely on 12-step model		
81% patient dropout rate in first 30 days for behavior only based programs	Poor patient compliance and adherence	Long-lasting medication that does not rely on human compliance
50% of patients fail to take medication as prescribed	Low compliance	
Difficult to find/ enter facility for treatment and high cost	85% of people who abuse alcohol go untreated	Affordable and widely accessible treatment centers

Solution- Proprietary

BioCorRx[®] Recovery Program

A Medication-assisted Treatment (MAT) program for treating alcohol and opioid addiction that combines a Naltrexone Implant with structured counseling.

- **Naltrexone Implant**

- Opioid receptor antagonist that works in the brain's reward system, blocks the pleasant effects from alcohol and drugs
- Administered by a licensed physician in doctor's office, outpatient setting, procedure typically takes 15-20 minutes
- Medication lasts several months
 - Stable dosage reduces cravings
 - Implantation improves compliance

- **Counseling (virtual and in-person)**

- Patients receive 16 private sessions, over approximately 4-6 months
- Individualized program and plan, to address specific needs of patient
- Step-by-step approach for specific addiction and can include family and friend participation

7



BioCorRx® Recovery Program

- Treated several hundred patients since 2010
- Unprecedented Success Rates*
- Currently 11 treatment facilities in the U.S using the BioCorRx® Recovery Program
- Exclusive U.S and International distribution rights for the program**
- **Distribution agreement in place with potential to sell program to hundreds of centers nationwide.**

*Based on subjective surveys conducted by centers using our program in routine patient and family interviews at various time intervals

**BioCorRx owns the recovery program and has worldwide rights to the implant except for Australia and New Zealand.

BioCorRx vs. Other Programs

Other Treatment Solutions	BioCorRx Recovery Program
Poor treatment outcomes	Unprecedented success rate
Limited drug effectiveness	Lasts several months*
Traditional Residential Rehab can be expensive	Affordable; covered by some health plans
Decreased compliance	Implant removes need for routine medication or therapy
Lack of privacy	Completely confidential
Major interruption to life	No downtime from daily life

*in many patients can last up to 6-12 months depending on individual metabolism rates

9

Established Distribution



- Established business model
- National and local recruitment and media plans
- Documented counseling procedures
- Scalable business SOPs
- Repeatable business and training practices and processes

10



Strategic Partnerships


- Trinity Compound Solutions
- Licensees
- Outpatient Addiction Clinics
- Myriad Medical Marketing*
- Physical Medicine Center Network*

11




Financial Highlights

BioCorRx Quarterly Revenue Growth Goals




G*: Goal

BioCorRx Annual Revenue Growth Goals




14

BioCorRx Quarterly EBITDA Growth Goals



BioCorRx Annual EBITDA Growth Goals





Investment Summary

- Unique, proven business model with largely fragmented competition
- Opportunity to be a disruptor in a \$35 billion dollar market
- Grew program sales over 400% in 2014
- Took company from one location to 11 in just over a year
- Became cash flow positive in 2014
- Eliminated convertible debt
- Positioned for accelerated growth and expansion

